U.S., April 26 -- ClinicalTrials.gov registry received information related to the study (NCT06945068) titled 'An Open-label Study of GB261 in Refractory Seropositive Systemic Lupus Erythematosus' on April 10.
Brief Summary: The purpose of the study is to evaluate the safety and efficacy of CD20xCD3 T-cell engager (GB261) in patients with refractory seropositive systemic lupus erythematosus.
Study Start Date: June, 2025
Study Type: INTERVENTIONAL
Condition:
Systemic Lupus Erythematosus (SLE)
Intervention:
BIOLOGICAL: GB261
GB261 will be dosed according to the assigned group.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Wuhan Union Hospital, China
Information provided by (Responsible Party): Qiubai Li, Wuhan Union Hospital, Chin...